Money

Trump Administration Recognizes AI's Influence on Employment Markets

Kevin Hassett, a prominent economic advisor during the Trump administration, recently shed light on the transformative effects of artificial intelligence on the job market. His remarks underscored how AI is significantly boosting output per worker, prompting a potential shift in corporate hiring strategies, particularly for recent university graduates. Despite concerns about this trend, the broader economic landscape shows resilience, marked by strong GDP growth, suggesting that any labor market adjustments due to AI will likely be transient as new economic opportunities emerge.

AI's Role in Reshaping Workforce Dynamics

Kevin Hassett, a key economic figure from the Trump era, recently discussed artificial intelligence's profound influence on the employment sector. He pointed out that AI technologies are dramatically improving the efficiency of existing workers, leading to a scenario where businesses might scale back on recruiting new college graduates. Hassett shared these insights during a discussion on CNBC's 'Squawk Box', noting that firms are increasingly capable of achieving higher output with their current staff, thanks to AI integration. This trend could create a temporary lull in entry-level hiring.

Despite these potential shifts in employment patterns, Hassett emphasized the underlying strength of the economy. He highlighted robust growth in the U.S. gross domestic product during the second quarter of 2025, suggesting a healthy economic foundation. He posited that any slowdown in the labor market would be a brief phase, directly attributing this to the productivity gains enabled by AI. Hassett expressed confidence that the free market would quickly adapt to these changes, driven by increased output and income generation, leading to the emergence of new avenues for economic activity and spending.

Navigating the Economic Balancing Act of AI Efficiency

The discussion surrounding AI's potential to displace entry-level positions has been ongoing, but Hassett's recent statements represent a notable acknowledgment from the Trump administration. This administration has been a vocal proponent of AI advancement, with former President Donald Trump issuing executive directives aimed at streamlining regulations and fostering the development of AI infrastructure. Hassett's comments also coincided with efforts by Trump and his allies to direct public attention towards economic affordability. While Trump has often claimed a reduction in grocery prices, Hassett conceded that these costs have not actually decreased during the GOP president's second term.

Hassett further elaborated that despite the consistent high cost of groceries, consumer purchasing power has actually seen an increase. He expressed bewilderment that the administration was being blamed for the persistent pricing issues, staunchly defending their economic policies. His observations underscore a complex economic picture where technological advancements like AI are driving efficiency and productivity, yet simultaneously introducing challenges and shifts in the labor market and consumer pricing dynamics. The administration's stance reflects a balancing act, promoting technological growth while attempting to manage public perception of economic well-being.

Gilead Sciences Options: Decoding Big Money Moves

Significant financial players are making strategic moves in Gilead Sciences' (GILD) options market, indicating a divided outlook on the company's future stock performance. This surge in options trading, characterized by a mix of bullish calls and bearish puts, suggests that influential investors are positioning themselves based on anticipated shifts in GILD's market value. The analysis of these large-scale transactions provides valuable insights into the sophisticated strategies employed by institutional and high-net-worth individuals who often possess privileged information or a deeper understanding of market dynamics.

Benzinga's advanced options scanning tools recently detected a remarkable eleven options trades for Gilead Sciences. This level of concentrated activity is unusual and typically points to impending market developments. The overall sentiment among these substantial traders is fairly balanced, with approximately 54% expressing a bullish stance and 45% leaning bearish. Delving into the specifics, one put option accounted for a total value of $229,600, while ten call options represented a combined value of $1,131,181, highlighting a preference for potential upside gains.

Further examination of trading volumes and open interest reveals that major market participants are focusing on a price range between $100.0 and $135.0 for Gilead Sciences over the next three months. The average open interest for GILD options currently stands at 1364.33, with a total trading volume reaching 11,357.00. Over the past 30 days, both call and put option volumes and open interest have been closely monitored within this strike price corridor, providing a clear picture of the evolving market expectations.

Gilead Sciences, a prominent biopharmaceutical company, is renowned for its work in developing and commercializing treatments for life-threatening infectious diseases, particularly HIV and hepatitis B and C. The company's portfolio has expanded significantly through strategic acquisitions, including rights to the hepatitis C drug Sovaldi and the integration of CAR-T cell therapy Yescarta/Tecartus from Kite, along with the breast and bladder cancer therapy Trodelvy from Immunomedics. These developments underscore Gilead's commitment to innovation and its growing presence in the oncology market.

As of recent trading, GILD's stock price registered a slight decrease of -0.19%, settling at $124.78, with a trading volume of 2,711,958. Current Relative Strength Index (RSI) indicators suggest that the stock might be nearing overbought territory. Analysts have offered varied perspectives on Gilead Sciences, with an average target price of $131.0 over the past month. Ratings range from 'Buy' by TD Cowen and Needham, with target prices of $125 and $140 respectively, to a 'Sector Perform' by RBC Capital at $105. Truist Securities recently lowered its rating to 'Buy' with a $145 target, while Scotiabank downgraded its action to 'Sector Outperform' with a $140 target. This diverse range of expert opinions reflects the complex outlook for the company's stock.

Monitoring the options trading activity of major investors can offer valuable insights into the anticipated trajectory of Gilead Sciences' stock. While options trading carries inherent risks, staying informed about market movements and expert analyses is crucial for making educated decisions. The current dynamics suggest that GILD is at a pivotal point, with significant capital flowing into bets on its future price direction.

See More

Johnson & Johnson Expands Oncology Portfolio with $3 Billion Acquisition of Halda Therapeutics, Bolstering Prostate Cancer Pipeline

Johnson & Johnson has significantly bolstered its pharmaceutical endeavors with a dual announcement: a major acquisition aimed at advancing cancer treatment and promising new clinical trial results for an existing autoimmune disease therapy. The company has moved to purchase Halda Therapeutics, a biotechnology firm specializing in innovative oncology solutions, for an impressive sum exceeding $3 billion. This strategic investment is set to inject a new lead candidate for prostate cancer into J&J’s robust drug development pipeline. Simultaneously, J&J has unveiled positive long-term data for its drug Tremfya, demonstrating its sustained effectiveness in managing psoriatic arthritis. These developments underscore J&J’s commitment to expanding its therapeutic portfolio and addressing critical unmet medical needs across various disease areas.

Strategic Expansion in Oncology: The Halda Therapeutics Acquisition

Johnson & Johnson's latest strategic move involves a substantial cash acquisition of Halda Therapeutics OpCo, Inc., valued at approximately $3.05 billion. This deal is poised to significantly enhance J&J's presence in the oncology sector, specifically targeting prostate cancer. Halda Therapeutics is recognized for its unique Regulated Induced Proximity Targeting Chimera (RIPTAC) platform, which is designed to develop novel oral, targeted therapies for a variety of solid tumors. The lead compound from this platform, HLD-0915, is already in clinical trials for prostate cancer, presenting a promising avenue for future treatment options. The integration of Halda's platform and its lead candidate is expected to provide Johnson & Johnson with a long-term growth catalyst, extending its therapeutic reach beyond oncology into other disease states.

The acquisition of Halda Therapeutics represents a pivotal moment for Johnson & Johnson, as it not only strengthens their existing oncology pipeline but also introduces a groundbreaking technology. Halda’s RIPTAC platform offers a distinct approach to developing targeted therapies, holding the potential to revolutionize how various cancers, especially prostate cancer, are treated. J&J's Executive Vice President, Jennifer Taubert, emphasized that this acquisition brings an exciting lead asset for prostate cancer and a versatile platform capable of addressing multiple types of cancers and other diseases, positioning it as a significant driver for future growth. While the transaction is expected to finalize within the next few months, J&J anticipates a short-term dilution of 15 cents to its adjusted earnings per share in 2026, primarily due to financing costs and equity award charges related to Halda employees. This move strategically positions Johnson & Johnson at the forefront of innovative cancer research and development.

Advancements in Autoimmune Disease Treatment: Tremfya's Sustained Efficacy

In parallel with its oncology expansion, Johnson & Johnson has also provided compelling new data concerning Tremfya (guselkumab), a key product in its portfolio for autoimmune diseases. Recent findings from the Phase 3b APEX study, presented at the Inflammatory Skin Disease Summit 2025, indicate that Tremfya continues to demonstrate remarkable efficacy in alleviating the signs and symptoms of active psoriatic arthritis. The study showcased Tremfya's ability to significantly inhibit the progression of structural damage over a 48-week period. This sustained benefit was observed consistently across different dosing regimens, whether patients received Tremfya every four weeks (Q4W) or every eight weeks (Q8W), underscoring the drug's robust and prolonged therapeutic effect.

The detailed results from the APEX study highlight Tremfya's superior performance in preventing joint structural damage, showing a two-and-a-half-times greater ability to do so compared to placebo at Week 24. Furthermore, the drug consistently delivered clinically meaningful improvements in American College of Rheumatology response criteria (ACR50) rates, which continued to rise from Week 24 to Week 48 in both treatment groups. Notably, almost half of the patients who initially received a placebo and then transitioned to Tremfya at Week 24 achieved ACR50 by Week 48, further validating its effectiveness. The sustained inhibition of structural joint damage through Week 48 reinforces Tremfya's role as a critical treatment option for individuals suffering from active psoriatic arthritis, offering long-term relief and preventing disease progression. These positive clinical outcomes contribute to Johnson & Johnson's strong market position and commitment to improving patient care in the autoimmune disease landscape.

See More